Wednesday, June 10, 2026
🇺🇸 FDA

Drug profile · INN

angiotensin

angiotensin is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 14
Pipeline programs 4
News articles 0
Drug details — angiotensin
Class
—
Route
—
Patents
14
Programs
4
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

angiotensin is an FDA-listed pharmaceutical active ingredient.

Key facts

INN angiotensin

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Search pipeline
  1. Icatibant Phase 3 · Takeda · Angiotensin Converting Enzyme Inhibitor Induced Angioedema
  2. Angiotensin (1-7) Phase 2 · United Therapeutics Europe · Traumatic Brain Injury
  3. Normal Saline (NS) .9% 10 mL Injection Phase 1 · Blackmores Institute · Ovarian Failure
  4. Renin-angiotensin system blockers Approved · Hospital Authority · Diabetes

Related patents

Browse patents

  1. US 2025195525

    ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OF SYSTEMIC DISEASES IN CATS

    Expires Wed Jun 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11891638

    Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)

    Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11078471

    Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10443049

    Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)

    Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9670473

    Crystals of angiotensin-converting enzyme (ACE)

    Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8895755

    Intermediates for preparing dual-acting benzyl triazole antihypertensive agents having angiotensin II type I receptor antagonist activity and neprilysin-inhibition activity

    Expires Mon Nov 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8569351

    Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity

    Expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7378108

    Percutaneous absorption preparation of compound having angiotensin II antagonistic activity

    Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 6521659

    Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

    Expires Mon Feb 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  10. US 6420405

    Pharmaceutical composition for angiotensin II-mediated diseases

    Expires Mon Jul 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  11. US 6348481

    Pharmaceutical composition for angiotensin II-mediated diseases

    Expires Mon Feb 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  12. US 6228874

    Pharmaceutical composition for angiotensin II-mediated diseases

    Expires Mon May 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  13. US 6194460

    Composition for treating cough induced by angiotensin converting enzyme inhibitors

    Expires Mon Feb 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  14. US 6100252

    Heterocyclic compounds and their use as angiotensin antagonists

    Expires Mon Aug 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is angiotensin?

angiotensin is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.